Dr. Daniel Rivlin, MD

Dr. Rivlin practices at Surgery Center of Aventura in Aventura, Florida.

Dr. Rivlin's NPI, 1073518692, was assigned on June 20, 2005. Dr. Rivlin graduated from New York University School of Medicine in 1987. Dr. Rivlin holds Florida license ME54696.

Dr. Rivlin's primary practice is Surgery Center of Aventura, at 20601 E Dixie Hwy Suite 400, Aventura, FL 33180. The practice phone is (305) 792-0323.

Dr. Rivlin's primary practice is Surgery Center of Aventura in Aventura, Florida. The medical group on file is Skin and Cancer Associates. Dmand AI also links Dr. Rivlin to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rivlin practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatopathology is Dr. Rivlin's primary specialty in the NPI Registry, under taxonomy code 207ND0900X. Dr. Rivlin is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Rivlin's licenses on file in 3 states: Florida, California and New York.

Dmand AI lists acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, contact dermatitis, facial skin infection, hives, itchy rashes and minor injury on trunk among the conditions Dr. Rivlin treats.

CMS data shows 16,536 Medicare services from Dr. Rivlin across 34 procedure codes in 2024, for 6,104 Medicare patients. Medicare paid $1,306,933 for them. Every service was in an office.

CMS counts 6,104 Medicare patients who saw Dr. Rivlin in 2024. The largest group is 65 to 74, with 2,544 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 3% are also on Medicaid. Their average risk score is 1.19, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Rivlin's median patient age at 68, with 47% women.

In 2024, Dr. Rivlin wrote 947 Medicare Part D claims for 554 patients. 96% of them were for generic drugs. CMS names the drug for 808 of them, across 14 drugs with 11 or more claims each, at $158,179 in total drug cost. In 2023, CMS named 801 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Rivlin for performance year 2024, reported individually. Dr. Rivlin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 72 procedures of melanoma (skin cancer) excision by Dr. Rivlin, more than 90% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 4 papers to Dr. Rivlin, published from 2020 to 2024. Dr. Rivlin has published most often in Int J Dermatol. Dr. Rivlin's most frequent co-authors are Gregory Bartos, DO, Angela P. Combs, DO and Jordan S. Fabrikant, DO.

CMS Open Payments shows 283 general payments to Dr. Rivlin from 45 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. LEO Pharma Inc. paid the most, $840.

Dmand AI lists 3 awards for Dr. Rivlin.

Dr. Rivlin graduated from New York University School of Medicine in 1987. Dr. Rivlin is a member of AAD and ASDS.

Dr. Rivlin is in network with 19 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.